Logo image
Back
Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias
Journal article   Peer reviewed

Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias

Joel Morganroth, Peter Pool, Ronald Miller, Ping-Hwa Hsu, Ian Lee, Donna M. Clark, The ENCAINIDE RESEARCH GROUP and Inae Lee
The American journal of cardiology, v 57(10), pp 769-774
1986
DOI: https://doi.org/10.1016/0002-9149(86)90611-9
PMID: 3083665
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

A multicenter, 2-week, double-blind, placebo-controlled, parallel group study was performed to determine the dose-response relation of encainide administered 3 times daily and to determine its onset of action. To be included in the study, patients with benign or potentially lethal ventricular arrhythmias were required to have an average of at least 30 ventricular premature complexes (VPCs) per hour on 48-hour Holter monitoring after a 48-hour washout period without antiarrhythmic drug treatment. Patients were randomly assigned to receive either placebo or 10, 25 or 50 mg of encainide 3 times daily (tid) for 2 weeks. Of the 125 patients who entered the study, 122 were available for efficacy analysis. Efficacy was determined using 24-hour Hoter monitoring on days 1, 7 and 14. There was no difference in frequency of VPCs or of ventricular tachycardia events in the placebo and 10-mg-tid encainide arms. At doses of 25 and 50 mg of tid, encainide was effective in suppressing VPCs and in reducing the number of episodes of ventricular tachycardia. A positive dose-response relation was identified. The onset of effect of encainide was apparent at 3 hours and lasted for 24 hours with tid dosing. No difference in on-therapy conditions were found among the 4 study arms. No patients were discontinued from the study because of electrocardiographic changes. There was no statistically significant change in vital signs or physical examination data. In 1 patient an elevated serum glucose level developed. No symptomatic proarrhythmic events occurred and none required discontinuation of study medication. Three patients died, 2 while receiving 50 mg tid and 1 patient while receiving 10 mg tid of encainide. Encainide's minimal effective dose for suppressing benign or potentially lethal ventricular arrhythmias is 25 mg tid.

Metrics

4 Record Views
22 citations in Web of Science
21 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image